- Consolidated sales of €45.9 million, -5.3% at constant exchange
rates
- Limited decrease in EBITDA (-4.2%) to €10.8 million, giving a
margin of 23.6%
- Recurring Operating Profit of €2.0 million
- Cash and cash equivalents of €36.5 million at December 31,
2020
Regulatory News:
Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker:
AMPLI, eligible for PEA-PME plans) (“Amplitude” or the
“Group”), leading French player on the global surgical
technology market for lower-limb orthopedics, today announced its
results for the first half of its 2020-21 financial year to
December 31, 2020.
Olivier Jallabert, Amplitude Surgical’s CEO, commented:
“In the first half of our 2020-21 financial year, Amplitude
Surgical’s activity was impacted, during the second quarter, by the
deterioration in the public health situation associated with
COVID-19 on the majority of its markets and by the adoption of
restrictions on access to operating rooms. Despite the 5.3% fall in
activity at constant exchange rates, the improvement in the gross
margin thanks to a positive country mix and the optimization of our
production tools, combined with good cost control, enabled us to
limit the decrease in EBITDA to 4.2%, at €10.8 million, and to
record a Recurring Operating Profit of €2.0 million. Despite the
health context, the Group continues to develop, particularly in
R&D, with automation projects for surgical procedures. In
addition, Amplitude Surgical remains attentive to external growth
opportunities by exploring the acquisition of competitors or
agents, both in France and abroad”.
Financial summary - actual exchange rates:
€m - IFRS
H1 2020-21
H1 2019-20
Δ
Sales
45,909
49,833
-7.9%
Gross margin
34,939
36,277
-3.7%
as a % of sales
76.1%
72.8%
+330 bps
Sales & Marketing costs
16,413
17,582
-6.6%
General & Administrative costs
6,225
5,161
+20.6%
Research & Development costs
1,469
2,223
-33.9%
EBITDA
10,832
11,311
-4.2%
as a % of sales
23.6%
22.7%
+90 bps
Recurring Operating Profit
2,042
826
Non-recurring operating
income/expenses
-887
7,524
Operating profit/loss
1,156
8,350
Financial profit/loss
-6,220
-2,831
Net profit/loss - Group share
-4,984
5,300
Net financial debt
114,521
107,691
Net cash position at end of
period
36,497
19,108
EBITDA down 4.2%, with an improvement in the margin to
23.6%
Over the first half of the 2020-21 financial year (from July to
December), Amplitude Surgical recorded sales of €45.9 million, down
7.9% in actual terms and 5.3% at constant exchange rates compared
with the previous year, impacted by the deterioration in the public
health situation associated with the COVID-19 pandemic.
- In France, the Group recorded sales of €29.6
million (-2.6%) impacted by the second wave of the COVID-19
pandemic during the second quarter of its financial year (October -
December 2020) and the adoption of restrictions on access to
operating rooms from October 2020. France accounted for 64% of
total sales;
- International activity generated sales of €16.3 million,
down 16.1% in actual terms and 9.6% at constant exchange rates. The
Group’s subsidiaries recorded a 13.3% fall in sales (-4.4% at
constant exchange rates) to €12.5 million, subsidiaries’ activity
notably being impacted by the public health situation associated
with COVID-19 in Brazil, Germany and Australia. Activity with
distributors also weakened, falling 24.2% to €3.8 million;
- Amplitude Surgical’s direct business (French market and
international subsidiaries), which accounted for almost 92% of the
Group’s total sales, slipped 3.1% at constant exchange rates;
- Sales generated by Novastep, innovative solutions for
foot and ankle surgery, continued to grow in the first half and
totaled €6.1 million (+25.1% at constant exchange rates), driven by
the United States (+42.0% at constant exchange rates). Novastep now
accounts for approximately 13% of the Group’s sales.
Amplitude Surgical recorded a gross margin of 76.1%, an
improvement of 330 bps compared with the first half of 2019-20,
thanks to a more positive country mix than the previous year and to
the optimization of the Group’s production tools.
Operating expenses totaled €24.1 million, a 3.4% reduction
compared with December 2019.
The 20.6% increase in General & Administrative costs to €6.2
million corresponds primarily to the change in the allocation of
quality control and regulatory expenses of approximately €1
million, booked as R&D expenses in 2019/2020.
In the first half of 2020/2021, Research & Development
expenses stood at 3.2% of sales.
Amplitude Surgical had a workforce of 442 staff at the end of
December 2020, versus 436 at the end of June 2020 and 426 at the
end of December 2019. Personnel costs were down 2.1% compared with
the first half of 2019-2020.
EBITDA was thus €10.8 million, down 4.2%, giving a margin of
23.6%, up 90 bps compared with the first half of 2019-20.
The Group generated a Recurring Operating Profit of €2.0
million, compared with €0.8 million in the first half of 2019/2020,
thanks to good control over its operating costs. There was an
Operating Profit of €1.1 million, versus a figure of €8.4 million
in the first half of 2019/2020 that was bolstered by the €8.6
million reversal of the provision relating to “Taxation on Medical
Devices”.
The Financial Result was -€6.2 million, and consisted primarily
of an interest expense of €5.2 million and net currency exchange
losses of €1.0 million.
Financial Structure: cash of €36.5 million at the end of
2020
The net cash flow generated by operating activity amounted to a
negative €1.0 million over the half, versus a positive €7.4 million
in the first half of 2019-20, notably due to a €2.6 million
decrease in operating cash flow and to the change in Working
Capital Requirements, with cash burn of €4.4 million that was
reconstituted following the low level of June 30, 2020 due to the
first wave of the pandemic.
Investments totaled €4.3 million in the first half of 2020-21,
versus €5.2 million the first half of the previous year.
At end-December 2020, the Group had cash and cash equivalents of
€36.5 million. Its Net Financial Debt was €114.5 million, giving
gearing (Net Financial Debt over Shareholders’ Equity) of 1.73,
compared with 1.52 at end-June 2020.
Key first-half events
- Amplitude SAS’ request to invalidate the adjustment in its
dispute with URSSAF is rejected
On November 3, 2020, the Valence Judicial Court rejected
Amplitude SAS’ request to invalidate the €5.8 million adjustment in
its dispute with URSSAF (employee and employer social security
contribution collecting agency) pertaining to tax on the promotion
of medical devices for the period from July 1, 2014 to June 30,
2017. Amplitude has decided to appeal this decision.
- Change in control of Amplitude Surgical
- On November 10, 2020, Amplitude Surgical announced the
acquisition of a majority stake in its share capital by PAI
Partners.
Apax Partners, Olivier Jallabert and certain other managers and
senior executives of the Company divested 20,889,437 Amplitude
Surgical shares and undertook the contribution in kind of 4,121,120
Amplitude Surgical shares to Auroralux SAS, a company controlled by
PAI Partners, i.e. a total of 25,010,557 Amplitude Surgical shares
representing approximately 52.3% of the Company’s share capital, at
a price of €2.15 per share.
- On December 7, 2020, Auroralux sent the AMF the draft
information document and draft simplified public tender offer for
22,649,678 Amplitude Surgical shares at €2.15 per share.
- Amplitude Surgical sent the AMF, also on December 7, 2020, its
draft response to the Auroralux simplified public tender for the
Company’s shares at €2.15 per share.
- On January 5, 2021, the AMF issued a compliance notice
regarding the simplified public tender offer tabled by Auroralux
for Amplitude Surgical’s shares at €2.15 per share. The offer
period ran from January 7 to January 27, 2021 inclusive.
At the closing of the offer, Auroralux SAS held 34,906,476
Amplitude Surgical shares representing a similar number of voting
rights, i.e. 73.02% of the share capital and voting rights.
- Refinancing of the bond debt
Within the framework of the change in control of Amplitude
Surgical with the investment of PAI Partners, on November 10, 2020
the Company issued a bond of €110 million subscribed by Tikehau and
proceeded with the early repayment of the 2014 and 2016 bonds whose
outstanding amount was €96.6 million (excluding accrued interest)
at June 30, 2020.
Amplitude Surgical's operations in Japan
Considering all of the Group's projects and in order to optimize
the allocation of its capital, the Group has decided to stop its
operations in Japan. This decision will be implemented in the
coming months.
Impact of the COVID-19 pandemic on the Group’s activity in
early 2021
The public health situation associated with the COVID-19
pandemic has remained unsettled on the Group’s various markets in
the early part of the second half of its 2020/2021 financial year,
with restrictions on access to operating rooms and the postponement
of patient consultations.
- Group sales for the period from July 1, 2020 to January 31,
2021 totaled €55.5 million, representing an 8.5% decrease compared
with the same period of the previous financial year, with the
public health situation having more of an impact in January
2021;
- In January 2021, Group sales were down 11.4% and EBITDA down
21% compared with January 2020; and
- The EBITDA margin for the period from July 1, 2020 to January
31, 2021 was around 24%.
Availability of the financial report
Amplitude Surgical has made available to the public and filed
with the Autorité des marchés financiers its half-year financial
report as of December 31, 2020.
The half-year financial report is available on Amplitude
Surgical's website at www.amplitude-surgical.com/fr, in the
"Documentation / Financial Report" section.
Next press release:
Sales for the first 9 months of 2021-22, on Thursday April
22, 2021 (after market).
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a
leading French player on the global surgical technology market for
lower-limb orthopedics. Amplitude Surgical develops and markets
high-end products for orthopedic surgery covering the main
disorders affecting the hip, knee and extremities, and notably foot
and ankle surgery. Amplitude Surgical develops, in close
collaboration with surgeons, numerous high value-added innovations
in order to best meet the needs of patients, surgeons and
healthcare facilities. A leading player in France, Amplitude
Surgical is developing abroad through its subsidiaries and a
network of exclusive distributors and agents distributing its
products in more than 30 countries. Amplitude Surgical operates on
the lower-limb market through the intermediary of its Novastep
subsidiaries in France and the United States. At June 30, 2020,
Amplitude Surgical had a workforce of 436 employees and recorded
sales of nearly 88 million euros.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210324005574/en/
Amplitude Surgical Dimitri Borchtch CFO
finances@amplitude-surgical.com +33 (0)4 75 41 87 41
NewCap Investor Relations Mathilde Bohin/Thomas Grojean
amplitude@newcap.eu +33 (0)1 44 71 94 94
NewCap Media Relations Nicolas Merigeau
amplitude@newcap.eu +33 (0)1 44 71 94 98
Amplitude Surgical (EU:AMPLI)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Amplitude Surgical (EU:AMPLI)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024